Arax Advisory Partners’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.5M | Buy |
449,006
+443,105
| +7,509% | +$19M | 0.14% | 152 |
|
|
2026
Q1 | $217K | Sell |
5,901
-7,264
| -55% | -$344K | 0.01% | 1045 |
|
|
2025
Q4 | $670K | Sell |
13,165
-7,817
| -37% | -$400K | 0.02% | 489 |
|
|
2025
Q3 | $1.16M | Buy |
20,982
+17,665
| +533% | +$1.03M | 0.02% | 602 |
|
|
2025
Q2 | $271K | Sell |
3,317
-3,218
| -49% | -$219K | 0.01% | 557 |
|
|
2025
Q1 | $454K | Sell |
6,535
-1,389
| -18% | -$115K | 0.03% | 332 |
|
|
2024
Q4 | $682K | Buy |
7,924
+4,315
| +120% | +$467K | 0.04% | 230 |
|
|
2024
Q3 | $430K | Sell |
3,609
-28
| -0.8% | -$3.73K | 0.04% | 224 |
|
|
2024
Q2 | $519K | Sell |
3,637
-158
| -4% | -$20.9K | 0.05% | 183 |
|
|
2024
Q1 | $487K | Sell |
3,795
-183
| -5% | -$21.8K | 0.05% | 180 |
|
|
2023
Q4 | $411K | Buy |
3,978
+1,689
| +74% | +$167K | 0.05% | 186 |
|
|
2023
Q3 | $208K | Buy |
2,289
+153
| +7% | +$13.5K | 0.03% | 252 |
|
|
2023
Q2 | $173K | Buy |
2,136
+16
| +0.8% | +$1.31K | 0.02% | 264 |
|
|
2023
Q1 | $169K | Buy |
2,120
+186
| +10% | +$13.2K | 0.02% | 263 |
|
|
2022
Q4 | $131K | Sell |
1,934
-36
| -2% | -$2.11K | 0.02% | 290 |
|
|
2022
Q3 | $98K | Buy |
1,970
+176
| +10% | +$9.43K | 0.02% | 314 |
|
|
2022
Q2 | $100K | Buy |
1,794
+712
| +66% | +$39.5K | 0.02% | 315 |
|
|
2022
Q1 | $60K | Buy |
1,082
+996
| +1,158% | +$51.1K | 0.01% | 424 |
|
|
2021
Q4 | $5K | Buy |
86
+70
| +438% | +$3.79K | ﹤0.01% | 769 |
|
|
2021
Q3 | $1K | Buy |
+16
| New | +$774 | ﹤0.01% | 922 |
|
|
2020
Q4 | $8K | Hold |
232
| – | – | ﹤0.01% | 595 |
|
|
2020
Q3 | $8K | Buy |
232
+2
| +0.9% | +$67 | ﹤0.01% | 566 |
|
|
2020
Q2 | $8K | Buy |
230
+2
| +0.9% | +$64 | ﹤0.01% | 560 |
|
|
2020
Q1 | $7K | Hold |
228
| – | – | ﹤0.01% | 553 |
|
|
2019
Q4 | $7K | Hold |
228
| – | – | ﹤0.01% | 497 |
|
|
2019
Q3 | $6K | Hold |
228
| – | – | ﹤0.01% | 505 |
|
|
2019
Q2 | $6K | Buy |
+228
| New | +$5.63K | ﹤0.01% | 507 |
|
|
2018
Q4 | $5K | Sell |
224
-154
| -41% | -$3.42K | ﹤0.01% | 490 |
|
|
2018
Q3 | $9K | Sell |
378
-2,328
| -86% | -$56.8K | ﹤0.01% | 478 |
|
|
2018
Q2 | $62K | Sell |
2,706
-88
| -3% | -$2.09K | 0.03% | 203 |
|
|
2018
Q1 | $68K | Sell |
2,794
-7,300
| -72% | -$192K | 0.04% | 174 |
|
|
2017
Q4 | $270K | Buy |
10,094
+40
| +0.4% | +$1.02K | 0.12% | 73 |
|
|
2017
Q3 | $242K | Sell |
10,054
-326
| -3% | -$7.37K | 0.12% | 75 |
|
|
2017
Q2 | $223K | Buy |
10,380
+618
| +6% | +$12.5K | 0.11% | 84 |
|
|
2017
Q1 | $167K | Buy |
9,762
+2,814
| +41% | +$49K | 0.08% | 86 |
|
|
2016
Q4 | $125K | Buy |
+6,948
| New | +$126K | 0.06% | 96 |
|
Other funds holding NVO
F
Arax Advisory Partners's NVO Position: Q2 2026 in Review
Arax Advisory Partners increased its Novo Nordisk (NVO) stake by 7,509% in Q2 2026, buying an estimated $19M and bringing the position to 449,006 shares worth $21.5M. The position accounts for 0.14% of the portfolio, ranked #152.
Arax Advisory Partners first reported a position in NVO in Q4 2016 and has held it in 36 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Arax Advisory Partners held 449,006 shares of Novo Nordisk worth $21.5M as of Q2 2026.
- Arax Advisory Partners bought 443,105 Novo Nordisk shares in Q2 2026, an estimated $19M.
- Novo Nordisk made up 0.14% of Arax Advisory Partners's portfolio in Q2 2026, its #152 holding.
- Arax Advisory Partners first reported a position in Novo Nordisk in Q4 2016 and has held it in 36 quarters since.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.